Recent advances of IMiDs in cancer therapy

@article{Li2010RecentAO,
  title={Recent advances of IMiDs in cancer therapy},
  author={Shirong Li and Navkiranjit Gill and Suzanne Lentzsch},
  journal={Current Opinion in Oncology},
  year={2010},
  volume={22},
  pages={579–585}
}
Purpose of review Immunomodulatory derivatives of thalidomide (IMiDs) have been used for the treatment of myelodysplastic syndrome and multiple myeloma; however, the mechanism of action of IMiDs is largely unknown. The purpose of this review is to provide an overview of recent findings on the mechanism of action of IMiDs, its use as a new treatment modality for various hematologic malignancies, and problems associated with stem cell mobilization after lenalidomide treatment. Recent findings… Expand
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
TLDR
Combination therapy with lenalidomide plus dexamethasone provides a valuable option for the treatment of relapsed or refractory adult patients with multiple myeloma and significantly prolonged the median time to progression, increased overall response rates and prolonged overall survival. Expand
Spotlight on Lenalidomide in Relapsed or Refractory Multiple Myeloma
TLDR
In the pivotal MM-009 and MM-010 phase III registration trials, treatment with lenalidomide plus dexamethasone was effective and had a manageable safety and tolerability profile in relapsed or refractory patients with multiple myeloma. Expand
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
TLDR
CRBN is an essential requirement for IMiD activity and a possible biomarker for the clinical assessment of antimyeloma efficacy andGene expression changes induced by lenalidomide were dramatically suppressed in the presence of CRBN depletion, further demonstrating that CRBN is required for lenalidmide activity. Expand
Efficacy of thalidomide‐based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
TLDR
This retrospective study retrospectively studied 24 patients with advanced MM with relapsed disease, refractory disease, or intolerance to full dose lenalidomide and dexamethasone that were subsequently treated with a thalidomid-based regimen and responses for all 24 patients. Expand
Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation
TLDR
Continuous lenalidomide regimens provide an effective longer-term treatment option in patients with newly diagnosed multiple myeloma ineligible for stem-cell transplantation. Expand
Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma.
  • M. Cruz
  • Medicine
  • P & T : a peer-reviewed journal for formulary management
  • 2016
TLDR
This study evaluated continuous lenalidomide in combination with dexamethasone until disease progression versus melphalan, prednisone, and thalidomides for 18 months as the primary analysis. Expand
CCR New Strategies New Strategies in the Treatment of Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma that traditionally has been thought to possess the poor-risk features of both indolent lymphoma, with its incurability, andExpand
New Strategies in the Treatment of Mantle Cell Lymphoma
TLDR
The emergence of a more sophisticated understanding of the underlying pathogenesis, coupled with a host of new agents and targets, has again created new opportunities to improve the care of patients with MCL and may potentially affect the natural history of this disease. Expand
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
TLDR
Preliminary evidence of lenalidomide's activity in patients with rel/ref cHL is provided, and therefore exploration of len Khalidomide in combination with other active agents is warranted. Expand
On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs.
TLDR
F fluorination is identified to correlate both with CRBN binding affinity and with antiangiogenic effects, but a correlation between the latter two phenomena is not found, indicating that the main target for the antiangIogenic effects of thalidomide analogs still remains to be identified. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 38 REFERENCES
Lenalidomide: a novel anticancer drug with multiple modalities.
TLDR
The most significant development for lenalidomide has been its FDA approval (US and Europe) for previously treated multiple myeloma in combination with dexamethasone. Expand
Mechanism of action of lenalidomide in hematological malignancies
TLDR
Lenalidomide is a 4-amino-glutamyl analogue of thalidomides that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. Expand
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
TLDR
Based on in vitro data, it appears that anti-proliferative effects and downregulation of crucial cytokines are their most important anti-MM attributes. Expand
Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma.
TLDR
The combination of lenalidomide and rituximab has activity and is well tolerated with minimal toxicity in patients with newly diagnosed indolent lymphoma. Expand
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
TLDR
The data provide one explanation for adjuvant properties of lenalidomid and pomalidomide and suggest that they may help overcome an important barrier to tumour-specific immunity in cancer patients. Expand
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
TLDR
Early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization are recommended. Expand
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
  • T. Witzig, P. Wiernik, +10 authors J. Vose
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
Oral lenalidomide monotherapy produces durable responses with manageable adverse events in patients with relapsed/refractory indolent NHL, warranting further investigation of treatment for indolents NHL. Expand
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
TLDR
The addition of panobinostat to dexamethasone and either bortezomib or lenalidomide plus steroids resulted in clear potentiation in multiple myeloma cell lines, freshly isolated plasma cells, and murine models of multipleMyeloma. Expand
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
  • M. Lacy, S. Hayman, +17 authors S. Rajkumar
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
The combination of pomalidomide and low-dose dexamethasone is extremely active in the treatment of relapsed multiple myeloma, including high response rates in patients refractory to other novel agents. Expand
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
TLDR
It is shown that IMiDs down-regulate PU.1, a key transcription factor involved in granulocyte differentiation in vitro and in patients treated with lenalidomide, which results in transient maturation arrest with medullary accumulation of immature myeloid precursors and subsequent neutropenia. Expand
...
1
2
3
4
...